Teachers Retirement System of The State of Kentucky Purchases Shares of 26,708 MBX Biosciences, Inc. (NYSE:MBX)

Teachers Retirement System of The State of Kentucky purchased a new position in MBX Biosciences, Inc. (NYSE:MBX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 26,708 shares of the company’s stock, valued at approximately $694,000. Teachers Retirement System of The State of Kentucky owned about 0.08% of MBX Biosciences at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in MBX Biosciences in the 3rd quarter worth $278,000. Point72 Asset Management L.P. acquired a new position in shares of MBX Biosciences in the third quarter valued at about $405,000. Barclays PLC purchased a new position in shares of MBX Biosciences in the third quarter worth about $426,000. Geode Capital Management LLC purchased a new position in shares of MBX Biosciences in the third quarter worth about $579,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of MBX Biosciences during the third quarter worth about $624,000.

MBX Biosciences Stock Performance

Shares of NYSE MBX opened at $19.49 on Thursday. The stock’s 50 day moving average price is $21.18. MBX Biosciences, Inc. has a 12 month low of $15.31 and a 12 month high of $27.50.

MBX Biosciences (NYSE:MBX) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($2.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.72) by ($0.06). As a group, analysts forecast that MBX Biosciences, Inc. will post -13.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on MBX shares. JPMorgan Chase & Co. started coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Guggenheim initiated coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They set a “buy” rating and a $44.00 target price for the company. Jefferies Financial Group assumed coverage on shares of MBX Biosciences in a research report on Tuesday, October 8th. They set a “buy” rating and a $35.00 target price for the company. Finally, Stifel Nicolaus started coverage on MBX Biosciences in a research report on Tuesday, October 8th. They set a “buy” rating and a $40.00 price target on the stock.

MBX Biosciences Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.